Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Cancer Treatment: Present and Future of Radioligand Therapy
share announcement

Cancer Treatment: Present and Future of Radioligand Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 20 November 2025 | Viewed by 782

Special Issue Editors

Dr. Egesta Lopci

E-Mail Website
Guest Editor
Nuclear Medicine Unit, Humanitas Research Hospital-IRCCS, Via Manzoni 56, 20089 Rozzano, Italy
Interests: molecular imaging; positron emission tomography; cancer imaging; immunotherapy; treatment response assessment
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Akram N. Al-Ibraheem

E-Mail Website
Guest Editor
Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman 11941, Jordan
Interests: radiotheranostics; PET/CT; molecular imaging; radioligand therapy; cancer diagnosis; nuclear medicine

Special Issue Information

Dear Colleagues,

We are excited to invite you to contribute to this Special Issue on "Cancer Treatment: Present and Future of Radioligand Therapy". Radioligand therapy (RLT) is an innovative targeted cancer treatment approach that minimizes damage to healthy organs while allowing higher therapeutic doses. Recent years have seen PSMA-based RLT become routine for prostate cancer, with promising agents like fibroblast activation protein (FAPI), C-X-C chemokine receptor type 4 (CXCR4), glucagon-like peptide-1 receptor (GLP-1R), and gastrin-releasing peptide receptor (GRPR) under investigation. This Special Issue will explore crucial RLT topics, including dosimetry, patient selection, efficacy, safety, toxicity assessment, emerging therapies, the role of molecular imaging, and the advent of artificial intelligence (AI) and machine learning applications in RLT.

We look forward to receiving your contributions.

Dr. Egesta Lopci
Prof. Dr. Akram N. Al-Ibraheem
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radioligand therapy
  • PRLT
  • FAPI
  • PSMA
  • CXCR4
  • GRPR
  • GLP-1R
  • RLT
  • novel radiopharmaceutical
  • cancer theranostics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

24 pages, 1200 KiB  
Review
Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy
by Bojana Bogdanovic, Florent Hugonnet and Christopher Montemagno
Cancers 2025, 17(7), 1247; https://doi.org/10.3390/cancers17071247 - 7 Apr 2025
Viewed by 623
Abstract
Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, continue to challenge clinicians with complex treatment regimens that often involve significant side effects and limited success, especially in advanced stages. Recent advancements in nuclear medicine have introduced theranostic strategies that merge diagnostic imaging with [...] Read more.
Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, continue to challenge clinicians with complex treatment regimens that often involve significant side effects and limited success, especially in advanced stages. Recent advancements in nuclear medicine have introduced theranostic strategies that merge diagnostic imaging with targeted therapeutic approaches, offering the potential for more precise and personalized treatment. A key area of progress lies in the development of alpha-emitting radiopharmaceuticals, such as 225Ac, 211At, or 212Pb, which can deliver potent radiation directly to tumor cells, sparing healthy tissue and minimizing collateral damage. In parallel with these therapeutic advancements, molecular imaging using radiolabeled agents enables better disease monitoring, assessment of treatment efficacy, and personalized management of patients with hematologic malignancies. The integration of diagnostic imaging with radiotherapy allows for a more tailored approach, where treatment can be adjusted based on real-time information about tumor progression and response. This review examines the recent strides made in both the development of radiopharmaceuticals and their applications in molecular imaging, with a focus on the potential to improve precision, reduce toxicity, and optimize patient outcomes. The synergy between targeted therapy and molecular imaging represents a transformative shift in the management of hematologic malignancies. As these technologies evolve, they are poised to redefine treatment paradigms, offering new hope for patients and potentially improving survival rates with more effective and less toxic treatment options. Full article
(This article belongs to the Special Issue Cancer Treatment: Present and Future of Radioligand Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop